- Our Doctors
- Dr Swetha Sridharan
Dr Swetha Sridharan
FRANZCR, MBBS, Radiation Oncologist
For patients/carers
For doctors
FRANZCR, MBBS, Radiation Oncologist
Locations
Clinical interests
- Genitourinary cancer
- Gynaecological cancer
- Gastrointestinal cancer
- Liver cancer
- Kidney cancer (Renal cancer)
- Prostate cancer
Treatment techniques
- Radiation oncology
Languages
Fluent
- English
- Hindi / हिन्दी
Biography
Clinical interests include cancers of the lower gastrointestinal tract, urogenital system, gynaecological cancers, and liver and kidney cancers.
Dr Swetha Sridharan is a Radiation Oncologist based in Gateshead, NSW, with expertise in the management of genitourinary, gastrointestinal and gynaecological cancers. She is committed to delivering compassionate, evidence-based care and works collaboratively within multidisciplinary teams to develop personalised treatment plans, incorporating advanced radiotherapy techniques.
Recognised for her patient-centred approach and clear, empathetic communication, Dr Sridharan supports patients and their families throughout their cancer journey, while maintaining a strong focus on clinical excellence and ongoing professional development.
More information
- Royal Australian and New Zealand College of Radiologists (RANZCR)
- Trans Tasman Radiation Oncology Group (TROG)
- GOROC
- Shore, N. D., de Almeida Luz, M., De Giorgi, U., Gleave, M., Gotto, G. T., Pieczonka, C. M., Haas, G. P., Kim, C.-S., Ramirez-Backhaus, M., Rannikko, A., Kalac, M., Sridharan, S., Rosales, M., Tang, Y., Tutrone, R. F. Jr, Venugopal, B., Villers, A., Woo, H. H., Wang, F., & Freedland, S. J. (2025). Improved survival with enzalutamide in biochemically recurrent prostate cancer. The New England Journal of Medicine. Advance online publication. https://doi.org/10.1056/NEJMoa2510310
- Freedland, S. J., de Almeida Luz, M., De Giorgi, U., Gleave, M., Gotto, G. T., Pieczonka, C. M., Haas, G. P., Kim, C.-S., Ramirez-Backhaus, M., Rannikko, A., Kalac, M., Sridharan, S., Rosales, M., Tang, Y., Tutrone, R. F., Venugopal, B., Villers, A., Woo, H. H., Wang, F., … Shore, N. D. (2023). Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. The New England Journal of Medicine, 389(16), 1453–1465. https://doi.org/10.1056/NEJMoa2303974
- Siva, S., Chesson, B., Bressel, M., Pryor, D., Higgs, B., Reynolds, H. M., Hardcastle, N., Montgomery, R., Vanneste, B., Khoo, V., Ruben, J., Lau, E., Hofman, M. S., Lourenço, R. D. A., Sridharan, S., Brook, N. R., Martin, J., Lawrentschuk, N., Kron, T., & Foroudi, F. (2018). TROG 15.03 phase II clinical trial of focal ablative stereotactic radiosurgery for cancers of the kidney: FASTRACK II. BMC Cancer, 18(1), Article 1030. https://doi.org/10.1186/s12885-018-4916-2
Explore more
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.